Rezeptorvermittelte Chemotherapie gynäkologischer Tumoren und des Mammakarzinoms

Translated title of the contribution: Targeted chemotherapy of gynecological malignancies and breast cancer

J. B. Engel, Andrew V Schally, A. Hönig, J. Dietl

Research output: Contribution to journalArticle

Abstract

The current article reviews a novel approach in tumor therapy based on peptide hormon analogs of GnRH, Bombesin/GRP and Somatostatin as carrier substances for cytotoxic agents, thus aiming to achieve a higher concentration of the active compound in the vicinity of the tumor. This therapeutic concept should lead to an increased antitumoral efficacy and minimized side effects. Targeted therapy with cytotoxic analogs of GnRH, Bombesin/GRP and Somatostatin has been highly effective in preclinical tumor models of breast-, endometrial, and ovarian cancer, although associated with only a low haematological toxicity. In the current studies cytotoxic hybrid molecules were significantly more potent than the chemotherapeutic agent alone. However, the expression of the respective target receptor on the tumor cells is a necessary requirement for an effective therapy, as blockade of tumoral receptors significantly decreased the efficacy of the cytotoxic hybrid molecules in vivo. The haematological toxicity of targeted chemotherapy was significantly less pronounced than the corresponding nondirected therapy with a cytotoxic radical alone in all animal experiments. The rapid development of a resistance to targeted chemotherapy is unlikely, as the expression of MDR proteins after targeted therapy was not increased as compared to a corresponding non-targeted approach in all experiments. AN-152, one of the compounds investigated in this article has already entered clinical testing. Thus, AN-152 showed a good tolerability in a clinical phase I study for patients with GnRH-positive breast-, ovarian-, and endometrial cancer and is now tested for efficacy in a clinical phase II study.

Original languageGerman
Pages (from-to)145-151
Number of pages7
JournalTumor Diagnostik und Therapie
Volume31
Issue number3
DOIs
StatePublished - Jun 23 2010

Fingerprint

Breast Neoplasms
Drug Therapy
Gonadotropin-Releasing Hormone
Bombesin
Neoplasms
Endometrial Neoplasms
Somatostatin
Ovarian Neoplasms
Therapeutics
Cytotoxins
Peptides
Proteins
lysine(6)-doxorubicin LHRH

Keywords

  • Breast cancer
  • Chemotherapy
  • Cytotoxic hybrid molecules
  • Gynaecological tumors
  • Peptide hormone analogs as carrier substances
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Rezeptorvermittelte Chemotherapie gynäkologischer Tumoren und des Mammakarzinoms. / Engel, J. B.; Schally, Andrew V; Hönig, A.; Dietl, J.

In: Tumor Diagnostik und Therapie, Vol. 31, No. 3, 23.06.2010, p. 145-151.

Research output: Contribution to journalArticle

@article{5cc1f3b0c00a47bbaf74030aad1fa3ea,
title = "Rezeptorvermittelte Chemotherapie gyn{\"a}kologischer Tumoren und des Mammakarzinoms",
abstract = "The current article reviews a novel approach in tumor therapy based on peptide hormon analogs of GnRH, Bombesin/GRP and Somatostatin as carrier substances for cytotoxic agents, thus aiming to achieve a higher concentration of the active compound in the vicinity of the tumor. This therapeutic concept should lead to an increased antitumoral efficacy and minimized side effects. Targeted therapy with cytotoxic analogs of GnRH, Bombesin/GRP and Somatostatin has been highly effective in preclinical tumor models of breast-, endometrial, and ovarian cancer, although associated with only a low haematological toxicity. In the current studies cytotoxic hybrid molecules were significantly more potent than the chemotherapeutic agent alone. However, the expression of the respective target receptor on the tumor cells is a necessary requirement for an effective therapy, as blockade of tumoral receptors significantly decreased the efficacy of the cytotoxic hybrid molecules in vivo. The haematological toxicity of targeted chemotherapy was significantly less pronounced than the corresponding nondirected therapy with a cytotoxic radical alone in all animal experiments. The rapid development of a resistance to targeted chemotherapy is unlikely, as the expression of MDR proteins after targeted therapy was not increased as compared to a corresponding non-targeted approach in all experiments. AN-152, one of the compounds investigated in this article has already entered clinical testing. Thus, AN-152 showed a good tolerability in a clinical phase I study for patients with GnRH-positive breast-, ovarian-, and endometrial cancer and is now tested for efficacy in a clinical phase II study.",
keywords = "Breast cancer, Chemotherapy, Cytotoxic hybrid molecules, Gynaecological tumors, Peptide hormone analogs as carrier substances, Targeted therapy",
author = "Engel, {J. B.} and Schally, {Andrew V} and A. H{\"o}nig and J. Dietl",
year = "2010",
month = "6",
day = "23",
doi = "10.1055/s-0029-1245359",
language = "German",
volume = "31",
pages = "145--151",
journal = "Tumor Diagnostik und Therapie",
issn = "0722-219X",
publisher = "Georg Thieme Verlag",
number = "3",

}

TY - JOUR

T1 - Rezeptorvermittelte Chemotherapie gynäkologischer Tumoren und des Mammakarzinoms

AU - Engel, J. B.

AU - Schally, Andrew V

AU - Hönig, A.

AU - Dietl, J.

PY - 2010/6/23

Y1 - 2010/6/23

N2 - The current article reviews a novel approach in tumor therapy based on peptide hormon analogs of GnRH, Bombesin/GRP and Somatostatin as carrier substances for cytotoxic agents, thus aiming to achieve a higher concentration of the active compound in the vicinity of the tumor. This therapeutic concept should lead to an increased antitumoral efficacy and minimized side effects. Targeted therapy with cytotoxic analogs of GnRH, Bombesin/GRP and Somatostatin has been highly effective in preclinical tumor models of breast-, endometrial, and ovarian cancer, although associated with only a low haematological toxicity. In the current studies cytotoxic hybrid molecules were significantly more potent than the chemotherapeutic agent alone. However, the expression of the respective target receptor on the tumor cells is a necessary requirement for an effective therapy, as blockade of tumoral receptors significantly decreased the efficacy of the cytotoxic hybrid molecules in vivo. The haematological toxicity of targeted chemotherapy was significantly less pronounced than the corresponding nondirected therapy with a cytotoxic radical alone in all animal experiments. The rapid development of a resistance to targeted chemotherapy is unlikely, as the expression of MDR proteins after targeted therapy was not increased as compared to a corresponding non-targeted approach in all experiments. AN-152, one of the compounds investigated in this article has already entered clinical testing. Thus, AN-152 showed a good tolerability in a clinical phase I study for patients with GnRH-positive breast-, ovarian-, and endometrial cancer and is now tested for efficacy in a clinical phase II study.

AB - The current article reviews a novel approach in tumor therapy based on peptide hormon analogs of GnRH, Bombesin/GRP and Somatostatin as carrier substances for cytotoxic agents, thus aiming to achieve a higher concentration of the active compound in the vicinity of the tumor. This therapeutic concept should lead to an increased antitumoral efficacy and minimized side effects. Targeted therapy with cytotoxic analogs of GnRH, Bombesin/GRP and Somatostatin has been highly effective in preclinical tumor models of breast-, endometrial, and ovarian cancer, although associated with only a low haematological toxicity. In the current studies cytotoxic hybrid molecules were significantly more potent than the chemotherapeutic agent alone. However, the expression of the respective target receptor on the tumor cells is a necessary requirement for an effective therapy, as blockade of tumoral receptors significantly decreased the efficacy of the cytotoxic hybrid molecules in vivo. The haematological toxicity of targeted chemotherapy was significantly less pronounced than the corresponding nondirected therapy with a cytotoxic radical alone in all animal experiments. The rapid development of a resistance to targeted chemotherapy is unlikely, as the expression of MDR proteins after targeted therapy was not increased as compared to a corresponding non-targeted approach in all experiments. AN-152, one of the compounds investigated in this article has already entered clinical testing. Thus, AN-152 showed a good tolerability in a clinical phase I study for patients with GnRH-positive breast-, ovarian-, and endometrial cancer and is now tested for efficacy in a clinical phase II study.

KW - Breast cancer

KW - Chemotherapy

KW - Cytotoxic hybrid molecules

KW - Gynaecological tumors

KW - Peptide hormone analogs as carrier substances

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77953676475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953676475&partnerID=8YFLogxK

U2 - 10.1055/s-0029-1245359

DO - 10.1055/s-0029-1245359

M3 - Article

AN - SCOPUS:77953676475

VL - 31

SP - 145

EP - 151

JO - Tumor Diagnostik und Therapie

JF - Tumor Diagnostik und Therapie

SN - 0722-219X

IS - 3

ER -